Life Science Fundraising & Investment
24 March 2026 - Pre-day forums (Life Science Companies only), FIL (Feira Internacional de Lisboa)25-26 March 2026 - Main days, Lisbon Congress Centre, Lisbon, Portugalkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day Two - Western European Summer Time (WEST)
keyboard_arrow_leftSearch & Filter
search
Streams
Clear
Formats
Day Two - Western European Summer Time (WEST)
search
Streams
Clear
Formats
Showing 1 of 1 Streams
Early Innovation & Technology Translation
11:30 - 12:10
Global Hotbeds of Innovation: Where Will the Next Breakthroughs Come From?
- Mathias Frederiksen - Principal, Novartis Venture Fund
- Sascha Berger - Investment Director, NEOM
- Ester Sklarsky - Principal, Sound Bioventures
- Emilio Erazo-Fischer - Operating Partner, Asabys Partners
12:10 - 12:50
From Lab to Launch: How to Turn Academic Research into a Viable Biotech
- Deborah Sterling - Director, Sterne Kessler
- Marta Lesko - VP, Head of Neurology & Immunology Business Development, Merck KGaA
- Laura Ferguson - Director, Platform Technologies Search and Evaluation, AstraZeneca
- Michel de Baar - Executive Director, Business Development, Europe, Merck
- Johan Juhlin - CEO, Mavatar
Showing 1 of 1 Streams
Early Innovation & Technology Translation
14:00 - 14:50
Rare Diseases vs. Broad Indications: Where to Focus Early-Stage Innovation
- Lori Badura - Head of Global Partnering Rare Disease & Neuroscience, IPSEN
- Sten Sörensen - CEO, Cereno Scientific
- Linda McGoldrick - Board Director, Alvotech
14:50 - 15:40
Next-Gen Modalities: Beyond Antibodies and Small Molecules
- Christopher Church - Head of Technology Search & Evaluation, Biopharmaceuticals R&D, AstraZeneca
- Hiro Usuda - Scouting & Transaction Lead, Astellas
- Jonas Båtelson - CEO, Curacell
- Cristiana Pires - CEO, Asgard Tx
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams
Clear
Formats